NYSE American - Nasdaq Real Time Price ? USD OS Therapies Incorporated (OSTX) Follow Compare 2.4800 -0.0400 (-1.59%) As of 10:43 AM EST. Market Open. All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations OS Therapies to Present at The Spartan Capital Investor Conference NEW YORK, November 04, 2024--OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that Paul Romness, Chief Executive Officer, and Gerald Commissiong, Chief Business Officer, will present a corporate overview at The Spartan Capital Investor Conference. The conference is being held on November 4, 2024 at the Pierre Hotel in New York. The Company’s participation aligns with our comm Business Wire ? 10 days ago OSTX -1.59% Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on October 30 NEW YORK, October 30, 2024--OS Therapies (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, is pleased to invite investors to a webinar on October 30, 2024, at 4:15 p.m. ET. Business Wire ? 15 days ago OSTX -1.59% OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors NEW YORK, October 28, 2024--OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announced the appointments of Avril McKean Dieser, MA, JD and Olivier R. Jarry, MS, MBA as independent members of the Company’s Board of Directors. Collectively, Ms. McKean Dieser and Mr. Jarry bring over 50 years of biopharmaceutical executive decision-making experience to the Company, with a specific focus in comm Business Wire ? 16 days ago OSTX -1.59% OS Therapies to Present at the LD Micro Main Event XVII NEW YORK, October 24, 2024--OS Therapies (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announces that Paul Romness, Chief Executive Officer, and Gerald Commissiong, Chief Business Officer, will present a corporate overview at the LD Micro Main Event XVII. The conference is being held on October 28 – 30, 2024 at the Luxe Sunset Boulevard Hotel in Los Angeles. Business Wire ? 21 days ago OSTX -1.59% OS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit NEW YORK, October 17, 2024--OS Therapies (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announces that Paul Romness, Chief Executive Officer, will be presenting at the 2024 Maxim Healthcare Virtual Summit. The summit is being held virtually on October 15 – 17, 2024. Business Wire ? 28 days ago OSTX -1.59% OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Completes Last Patient Visit NEW YORK, October 03, 2024--OS Therapies (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announces that the last patient (Patient #41) enrolled in the AOST-2121 clinical trial (NCT04974008) of OST-HER2 in recurred, resected Osteosarcoma (OS) has completed their final radiographical evaluation at 52 weeks and the treatment period for the clinical trial has now ended. The Company is preparing to re Business Wire ? last month OSTX -1.59% OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates NEW YORK, September 13, 2024--OS Therapies (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced the development and in vitro concept data for two novel ADC therapeutic candidates leveraging the Company’s proprietary SiLinker? technology. The Company has completed target engagement tests for both therapeutic candidates and confirmed their therapeutic potential. These new constructs will Business Wire ? 2 months ago OSTX -1.59% OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models Folate receptor alpha targeting drug conjugate & hexa silanol exatecan (FRA-H) payloads tested in animal models of ovarian cancer Strong efficacy for FRA-H in KB and IGROV-1 mouse models of ovarian cancer Strong safety profile for FRA-H with no loss ... ACCESSWIRE ? 2 months ago OSTX -1.59% OS Therapies to Present at H.C. Wainright 26th Annual Global Investment Conference NEW YORK, September 05, 2024--OS Therapies (NYSE American: OSTX) ("OS Therapies" or "the Company"), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today announced its participation in the H.C. Wainright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, in New York City. The Company’s President & CEO Paul Romness, MPH, will deliver a virtual presentation highlighting the Company’s potentially pivotal fully-enrolled Phase 2b Business Wire ? 2 months ago OSTX -1.59% OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose NEW YORK, August 29, 2024--OS Therapies Incorporated (NYSE American: OSTX) ("OS Therapies" or "the Company"), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today announced that the last patient (Patient #41) enrolled in the AOST-2121 clinical trial (NCT04974008) of OST-HER2 in recurred, resected Osteosarcoma (OS) - has received its last treatment dose. This last patient is expected to complete its final radiological imaging evaluation as part of the 12-month Eve Business Wire ? 2 months ago OSTX -1.59% OS Therapies Appoints Borys Shor, PhD to ADC Advisory Board NEW YORK, August 22, 2024--OS Therapies (NYSE American: OSTX) ("OS Therapies" or "the Company"), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today announced that it has appointed Borys Shor, PhD to its Antibody Drug Conjugate (ADC) Advisory Board. In his role, Dr. Shor will assist the Company in the selection of antibody and payloads to be developed using the Company’s tunable ADC platform leveraging its proprietary pH-sensitive SiLinker? silicone linker techn Business Wire ? 2 months ago OSTX -1.59% OS Therapies Clarifies CUSIP of Common Stock NEW YORK, August 22, 2024--OS Therapies (NYSE American: OSTX) ("OS Therapies" or "the Company"), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today provided a clarification for market participants, specifically brokerage firms, regarding the Committee on Uniform Securities Identification Procedures (CUSIP) identifier of the Company’s common stock. Business Wire ? 2 months ago OSTX -1.59% OS Therapies Accepted Into Johnson & Johnson Innovation - JLABS ROCKVILLE, Md., August 19, 2024--OS Therapies (NYSE American: OSTX) ("OS Therapies" or "the Company"), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today announced that it has been accepted into Johnson & Johnson Innovation – JLABS. Through membership of JLABS, OS Therapies aims to further develop and enter the clinic with its tunable Antibody Drug Conjugate (ADC) linker-based platform that relies on pH sensitive linkers & coating technology to reduce off-targe Business Wire ? 2 months ago OSTX -1.59% OS Therapies Reports Second Quarter 2024 Financial Results Successful IPO that raised $6.4 million on July 31, 2024, without issuing any warrants, occurred after the end of the second quarter and is not reflected in reported financials Conversion of all reported outstanding preferred shares and debt into ... ACCESSWIRE ? 2 months ago OSTX -1.59% OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV ORLANDO, FL / ACCESSWIRE / August 9, 2024 / RedChip Companies will air interviews with OS Therapies Inc. (NYSE American:OSTX) and Can-Fite BioPharma Ltd. (NYSE American:CANF) on the RedChip Small Stocks, Big Money? show, a sponsored program on Bloomberg ... ACCESSWIRE ? 3 months ago OSTX -1.59% CANF OS Therapies Announces Osteosarcoma Scientific and Medical Advisory Board ROCKVILLE, MD / ACCESSWIRE / August 6, 2024 /OS Therapies (NYSE American:OSTX) ("OS Therapies" or "the Company"), an Antibody Drug Conjugate (ADC) and Immunotherapy research and clinical-stage biopharmaceutical company, highlights its Scientific and ... ACCESSWIRE ? 3 months ago OSTX -1.59% OS Therapies Forms Osteosarcoma Patient Advocacy Advisory Board ROCKVILLE, Md. & NEW YORK, August 02, 2024--OS Therapies Incorporated ("OS Therapies" or the "Company") (NYSE-A: OSTX), a Cancer Immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced the formation of a Patient Advocacy Advisory Board (PAAB) for its osteosarcoma program. The purpose of the PAAB is to represent voices from the osteosarcoma community regarding the need for new therapies as the Company prepares to engage in discussions with the US Food & Drug Adm Business Wire ? 3 months ago OSTX -1.59% OS Therapies Announces Pricing of its Initial Public Offering on NYSE American - Company to Trade under Symbol "OSTX" ROCKVILLE, Md. & NEW YORK, July 31, 2024--OS Therapies Incorporated ("OS Therapies" or the "Company") (NYSE-A: OSTX), an Antibody Drug Conjugate (ADC) and Immunotherapy research and clinical stage biopharmaceutical company, today announced the pricing of its initial public offering of 1,600,000 shares of common stock at a public offering price of $4.00 per share, raising gross proceeds of $6.4 million. Additionally, the Company has granted the underwriters a 45-day option to purchase up to an ad Business Wire ? 3 months ago OSTX -1.59% OS Therapies Announces Positive Safety Data from Phase 1 Clinical Trial of OST-HER2 in HER2-Expressing Breast Cancer and in Preclinical Efficacy in Models of Breast Cancer ROCKVILLE, Md., July 24, 2024--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage oncology-focused immunotherapy company developing cancer vaccines and antibody drug conjugate (ADC) therapeutic candidates, today announced positive data from a Phase 1 clinical trial of OST-HER2 in patients with HER2-expressing solid tumors in breast cancer and other cancers. Additionally, the Company announced positive preclinical efficacy data for OST-HER2 in multiple models of breast cancer. Business Wire ? 3 months ago OSTX -1.59% OS Therapies Announces Positive Clinical Update from Ongoing Phase 2b Clinical Trial in Resected, Recurrent Osteosarcoma ROCKVILLE, Md., June 03, 2024--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage oncology-focused immunotherapy company developing cancer vaccines and antibody drug conjugate (ADC) therapeutic candidates, today announced a positive clinical update for AOST-2121 (NCT04974008), its ongoing Phase 2b clinical trial of its immunotherapy OST-HER2 (OST31-154) in patients with resected, recurrent osteosarcoma. Business Wire ? 5 months ago OSTX -1.59% Performance Overview Trailing total returns as of 11/14/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return OSTX S&P 500 YTD -38.00% +9.84% 1-Year -38.00% +9.84% 3-Year -38.00% +9.84%
